Trump: University of Miami Gives Ibogaine Investigational Drug Application to Federal Government

August 18, 2026
10:55 pm

▶

Listen to Article

The University of Miami’s decision to hand its ibogaine IND straight to the federal government is more than a drug-development footnote—it’s a live demonstration of how the administrative state can seize control of a promising compound the moment it shows real therapeutic value. Ibogaine has already compiled an impressive underground résumé for interrupting opioid addiction and traumatic brain injury symptoms, two conditions that disproportionately affect veterans and first responders. By moving the file from a private research institution into the hands of the same agencies that still classify cannabis as a Schedule I substance, the administration effectively places a potential life-saving therapy behind the same regulatory moat that has kept countless other plant-based medicines from reaching the public. For the 2A community this matters because the same bureaucratic architecture that can stall or bury ibogaine can just as easily be trained on ammunition, optics, or even the primers inside your reloading press. When regulators decide that a molecule—or a firearm component—carries “unacceptable risk,” the burden of proof shifts to citizens to prove their innocence rather than to the government to prove its case. The ibogaine transfer is therefore a cautionary tale: any expansion of federal oversight, no matter how well-intentioned on paper, creates precedent and personnel pipelines that future administrations can redirect toward the right to keep and bear arms. The practical takeaway is straightforward. Gun owners who also care about veterans’ access to cutting-edge treatments should watch this file the way they watch ATF rulemakings—because the regulatory state doesn’t silo its ambitions. If the feds can nationalize an investigational drug application overnight, they can nationalize a bracing system or redefine a semi-automatic trigger group just as quickly. Staying alert to these cross-domain power grabs is how the broader coalition of liberty-minded citizens keeps every front—medical, pharmaceutical, and firearms—defended at once.

Best FFL Software Ranked and Compared!

For the 2A community this matters because the same bureaucratic architecture that can stall or bury ibogaine can just as easily be trained on ammunition, optics, or even the primers inside your reloading press. When regulators decide that a molecule—or a firearm component—carries “unacceptable risk,” the burden of proof shifts to citizens to prove their innocence rather than to the government to prove its case. The ibogaine transfer is therefore a cautionary tale: any expansion of federal oversight, no matter how well-intentioned on paper, creates precedent and personnel pipelines that future administrations can redirect toward the right to keep and bear arms.

The practical takeaway is straightforward. Gun owners who also care about veterans’ access to cutting-edge treatments should watch this file the way they watch ATF rulemakings—because the regulatory state doesn’t silo its ambitions. If the feds can nationalize an investigational drug application overnight, they can nationalize a bracing system or redefine a semi-automatic trigger group just as quickly. Staying alert to these cross-domain power grabs is how the broader coalition of liberty-minded citizens keeps every front—medical, pharmaceutical, and firearms—defended at once.

Share this story